# Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)

> **NCT00297115** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1568 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00297115
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-04
- **Final completion:** 2008-08
- **Target enrollment:** 1568 (ACTUAL)
- **Last updated:** 2016-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00297115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00297115, "Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00297115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*